Michael Okunewitch

Q: How accurate are Michael Okunewitch's stock ratings?

About 41% of Michael's ratings were profitable over a one-year hold, with an average return of -5.5% per rating, measured by 13Foresight from historical prices.

Q: How is Michael ranked?

Michael Okunewitch is ranked #1078 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Maxim Group

Wall Street Analyst

★★★☆☆

#1078

on 13Foresight · ranked by our own returns

41%

Success Rate

-5.5%

Average Return

25 of 61 calls profitable · +31.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 41% of Michael Okunewitch's ratings turned a profit when each position was held for 1 year — averaging -5.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

116 Buy 12 Hold 0 Sell

Michael's Stock Coverage 29 ratings · 2026-09-05

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
EVAX Evaxion Biotech	Aug 26, 2026	BUY	Strong Buy +304.5% avg upside 6 analysts	$10.00 220.57% Upside	-3.7%	·
RANI Rani Therapeutics Holdings	Aug 20, 2026	BUY	Strong Buy +953.9% avg upside 10 analysts	$5.00 477.78% Upside	+0.1%	·
KPRX Kiora Pharmaceuticals	Aug 20, 2026	BUY	Strong Buy +251.0% avg upside 6 analysts	$12.00 370.55% Upside	-2.7%	·
VNRX VolitionRX	Aug 17, 2026	BUY	Strong Buy +2726.8% avg upside 11 analysts	—	-30.0%	·
MDWD Mediwound	Aug 14, 2026	BUY	Strong Buy +60.8% avg upside 13 analysts	$30.00 125.74% Upside	-1.8%	·
BLTE Belite Bio, Inc. ADR	Aug 14, 2026	BUY	Strong Buy +5.3% avg upside 11 analysts	$200.00 3.32% Upside	-1.3%	·
LGVN Longeveron	Aug 14, 2026	HOLD	Strong Buy +565.7% avg upside 4 analysts	—	-8.0%	·
DFTX Definium Therapeutics	Aug 13, 2026	BUY	Strong Buy +35.9% avg upside 22 analysts	$55.00 44.38% Upside	-13.4%	·
ACRV Acrivon Therapeutics, Inc.	Aug 13, 2026	BUY	Strong Buy +580.8% avg upside 13 analysts	$7.00 228.60% Upside	+15.1%	·
LCTX Lineage Therap	Aug 11, 2026	BUY	Strong Buy +411.9% avg upside 16 analysts	$3.00 177.87% Upside	-0.9%	·
CTOR Citius Oncology	Aug 10, 2026	BUY	Strong Buy +365.1% avg upside 1 analyst	$4.00 365.06% Upside	+16.5%	·
OCGN Ocugen	Aug 10, 2026	BUY	Strong Buy +581.0% avg upside 17 analysts	$8.00 488.26% Upside	+3.8%	·
CMPS COMPASS Pathways	Aug 07, 2026	BUY	Strong Buy +67.3% avg upside 20 analysts	$20.00 50.78% Upside	-2.2%	·
GILD Gilead Sciences	Aug 06, 2026	BUY	Strong Buy -21.6% avg upside 66 analysts	$165.00 9.25% Upside	+14.3%	·
ATAI Atai Beckley N.V.	Jul 17, 2026	HOLD	Buy +22.5% avg upside 17 analysts	—	+2.4%	·
CMMB Chemomab Therapeutics	Jul 13, 2026	BUY	Strong Buy +903.7% avg upside 6 analysts	$5.00 84.50% Upside	+71.5%	·
HCWB HCW Biologics	Jun 24, 2026	BUY	Strong Buy +920.4% avg upside 1 analyst	$30.00 920.35% Upside	-55.9%	·
AIDX 20/20 Biolabs, Inc.	May 21, 2026	BUY	Strong Buy +475.4% avg upside 2 analysts	$5.00 745.31% Upside	-51.2%	·
FBLG FibroBiologics, Inc.	May 04, 2026	HOLD	Buy +397.3% avg upside 4 analysts	—	+4.3%	·
NGEN NervGen Pharma	Apr 09, 2026	BUY	Strong Buy +317.0% avg upside 9 analysts	$12.00 415.06% Upside	-44.7%	·
BRTX BioRestorative Therapies	Apr 08, 2026	BUY	Strong Buy +5305.4% avg upside 3 analysts	$1.00 575.71% Upside	-42.4%	·
RADX Radiopharm Theranostics Limited Sponsored ADR	Mar 25, 2026	BUY	Strong Buy +781.4% avg upside 6 analysts	$15.00 621.08% Upside	-44.3%	·
QUCY Quantum Cyber	Mar 06, 2026	HOLD	Buy +151.5% avg upside 4 analysts	—	+91.6%	·
CTXR Citius Pharmaceuticals	Sep 23, 2025	HOLD	Buy +752.3% avg upside 3 analysts	—	-48.9%	·
ALZN Alzamend Neuro	Sep 13, 2025	HOLD	Buy +872.6% avg upside 2 analysts	$6.90 315.70% Upside	-29.4%	·
ANEB Anebulo Pharmaceuticals	Jul 24, 2025	HOLD	Buy +876.0% avg upside 5 analysts	—	-90.7%	·
ATHE Alterity Therapeutics	Mar 03, 2025	BUY	Strong Buy +117.3% avg upside 7 analysts	$12.00 164.23% Upside	-6.6%	·
LEXX Lexaria Bioscience	Sep 13, 2024	BUY	Strong Buy -39.7% avg upside 3 analysts	$12.00 15.14% Downside	-65.3%	·
CIRC Circle8 Group	May 09, 2023	BUY	Strong Buy +815.2% avg upside 2 analysts	—	·	·

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Michael Okunewitch — Frequently Asked Questions

How accurate are Michael Okunewitch's stock ratings?

Based on the calls 13Foresight could measure, about 41% of Michael's ratings were profitable over a one-year hold, with an average return of -5.5% per rating, or +38.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Michael ranked on 13Foresight?

Michael Okunewitch is currently ranked #1078 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Michael cover?

Michael most recently has ratings on EVAX, RANI, KPRX, VNRX, MDWD, BLTE, LGVN, DFTX, ACRV, LCTX, CTOR, OCGN and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Michael Okunewitch

Rating Distribution

Welcome to 13Foresight!